DrugPatentWatch Database Preview

TECHNIVIE Drug Profile

« Back to Dashboard

When do Technivie patents expire, and when can generic versions of Technivie launch?

Technivie is a drug marketed by Abbvie Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has three hundred and sixty patent family members in forty-five countries.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.

Summary for TECHNIVIE

International Patents:	360
US Patents:	10
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Clinical Trials:	2
Formulation / Manufacturing:	see details
Drug Prices:	see details
DailyMed Link:	TECHNIVIE at DailyMed

US Patents and Regulatory Information for TECHNIVIE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		RX	Yes	Yes			Y	Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		RX	Yes	Yes					Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		RX	Yes	Yes			Y	Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		RX	Yes	Yes

Expired US Patents for TECHNIVIE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015

Non-Orange Book US Patents for TECHNIVIE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,921,514	Anti-viral compounds
8,716,454	Solid compositions
8,333,990	Solid pharmaceutical dosage form
8,025,899	Solid pharmaceutical dosage form

International Patents for TECHNIVIE

Country	Document Number	Estimated Expiration
Dominican Republic	P2013000078
Argentina	094816
China	106986861
Israel	223269

Supplementary Protection Certificates for TECHNIVIE

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2017033	Lithuania		PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
667	Luxembourg		PRODUCT NAME: PARITAPREVIR, OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX). FIRST REGISTRATION: 20150119
/2015	Austria		PRODUCT NAME: PARITAPREVIR, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER ANNEHMBARER ESTER DAVON; REGISTRATION NO/DATE: (MITTEILUNG VOM 19.1.2015) EU/1/14/982 20150115
2015000039	Germany		PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115